Neuropace
Yahoo Finance • 12 days ago
3 Companies That May Be Priced Below Their Estimated Value
As the United States stock market navigates uncertainties such as potential government shutdowns and fluctuating commodity prices, major indices like the Dow Jones, Nasdaq, and S&P 500 have shown resilience with recent gains. In this envir... Full story
Yahoo Finance • 2 months ago
NeuroPace raises 2025 revenue guidance to $94M-$98M as RNS System drives record growth
Earnings Call Insights: NeuroPace, Inc. (NPCE) Q2 2025 MANAGEMENT VIEW * CEO Joel D. Becker highlighted a “record revenue quarter with strong revenue of $23.5 million, representing 22% growth compared to $19.3 million in the prior year... Full story
Yahoo Finance • 2 months ago
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the... Full story
Yahoo Finance • 3 months ago
NeuroPace's SWOT analysis: innovative epilepsy treatment stock faces growth hurdles
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company with a market capitalization of $341 million specializing in responsive neurostimulation for epilepsy treatment, has been making waves in the healthcare sector with its innovative RNS... Full story
Yahoo Finance • 4 months ago
NeuroPace stock rating reiterated at Overweight by Cantor Fitzgerald
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $16.00 price target on NeuroPace Inc (NASDAQ:NPCE) on Monday following the company’s announcement of a new chief financial officer. NeuroPace announced Monday the appo... Full story
Yahoo Finance • 4 months ago
NeuroPace appoints Patrick Williams as CFO
* NeuroPace (NASDAQ:NPCE [https://seekingalpha.com/symbol/NPCE]) has announced the appointment of Mr. Patrick F. Williams as CFO, effective June 20, 2025 [https://seekingalpha.com/pr/20146644-neuropace-announces-strategic-cfo-transition]... Full story
Yahoo Finance • 4 months ago
NeuroPace Announces Strategic CFO Transition
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 20... Full story
Yahoo Finance • 4 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newacti... Full story
Yahoo Finance • 4 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newacti... Full story
Yahoo Finance • 4 months ago
NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey
NeuroPace, Inc. (NASDAQ:NPCE) is among the best NASDAQ stocks under $50 to buy. Cantor Fitzgerald reiterated its Overweight rating on NeuroPace, Inc. (NASDAQ:NPCE), with a price target of $16.00, implying an upside of nearly 44%. This affi... Full story
Yahoo Finance • 4 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newacti... Full story
Yahoo Finance • 5 months ago
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary saf... Full story
Yahoo Finance • 6 months ago
NeuroPace Provides Update on Tariff Status
-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a... Full story
Yahoo Finance • 7 months ago
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 1... Full story
Yahoo Finance • 7 months ago
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at... Full story
Yahoo Finance • 7 months ago
NeuroPace to Present at the Leerink Partners Global Healthcare Conference
MOUNTAIN VIEW, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present a... Full story
Yahoo Finance • 8 months ago
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the previously announced... Full story
Yahoo Finance • 8 months ago
NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock
MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share... Full story
Yahoo Finance • 8 months ago
NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock
MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock. All of the shares a... Full story
Yahoo Finance • 8 months ago
NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th
MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the... Full story
